Endocrinology
Publications
Here you can review available Corcept-sponsored publications.
Information about investigational compounds or investigational uses of products does not imply FDA approval of these compounds or uses, nor does it establish the safety or efficacy of these compounds or uses. There is no guarantee that the investigational compounds or investigational uses of products will receive FDA approval. Corcept does not recommend or suggest use of its products in a manner inconsistent with FDA-approved labeling.
Access Corcept-sponsored publications below.
Filter by:
2026
Relacorilant
Efficacy and Safety of Relacorilant for the Treatment of Patients With Cushing’s Syndrome (GRACE): A Multicentre, Phase 3, Double-Blind, Placebo-Controlled, Randomised-Withdrawal Study
Pivonello R, Arnaldi G, Auchus RJ
2026
Investigating Endogenous Hypercortisolism Prevalence in a US Population with Resistant Hypertension: MOMENTUM Rationale and Design
Plutzky J, Taub PR, Bhatt DL, et al.
2025
Relacorilant
Relacorilant or surgery improved hemostatic markers in Cushing syndrome
Simeoli C, Di Paola N, Stigliano A, et al
2025
Mifepristone
Inadequately Controlled Type 2 Diabetes and Hypercortisolism: Improved Glycemia With Mifepristone Treatment
DeFronzo RA, Fonseca V, Aroda VR, et al
2025
Mifepristone
Identification of Endogenous Hypercortisolism and the Effect of Mifepristone Treatment in Patients With Difficult-to-Manage Diabetes: A Case Series
Lucci CP, McCoy G
2025
Prevalence of Hypercortisolism in Difficult-to-Control Type 2 Diabetes
Buse JB, Kahn SE, Aroda VR, et al.
2024
Relacorilant
Relacorilant, a Selective Glucocorticoid Receptor Modulator in Development for the Treatment of Patients With Cushing Syndrome, Does Not Cause Prolongation of the Cardiac QT Interval
Donegan DM, Pivonello R, Stigliano A, et al
2024
Mifepristone
Study protocol for a prospective, multicentre study of hypercortisolism in patients with difficult-to-control type 2 diabetes (CATALYST): prevalence and treatment with mifepristone
DeFronzo RA, Auchus RJ, Bancos I, et al
2022
Relacorilant
Corrigendum: Relacorilant, a Selective Glucocorticoid Receptor Modulator, Induces Clinical Improvements in Patients With Cushing Syndrome: Results From A Prospective, Open-Label Phase 2 Study
Pivonello R, Bancos I, Feelders RA, et al
2022
Relacorilant
Peripheral glucocorticoid receptor antagonism by relacorilant with modest HPA axis disinhibition
Viho EMG, Kroon J, Feelders RA, et al
2021
When to Suspect Hidden Hypercortisolism in Type 2 Diabetes: A Meta-Analysis
Aresta A, Soranna D, Giovanelli L, et al
2021
Hidden hypercortisolism: a too frequently neglected clinical condition
Giovanelli L, Aresta C, Favero V, et al.
2021
Relacorilant
Relacorilant, a Selective Glucocorticoid Receptor Modulator, Induces Clinical Improvements in Patients With Cushing Syndrome: Results From A Prospective, Open-Label Phase 2 Study
Pivonello R, Bancos I, Feelders RA, et al
2021
Mifepristone
Mifepristone as Bridge or Adjunct Therapy in the Management of Challenging Cushing Disease Cases
Chang AY, Mirfakhraee S, King EE, et al.
2020
Mifepristone
Clinical Management of patients with Cushing Syndrome treated with mifepristone: consensus recommendations
Brown DR, East HE, Eilerman BS, et al.
2019
Hypercortisolism in Newly Diagnosed Type 2 Diabetes: A Prospective Study of 384 Newly Diagnosed Patients
Steffensen C, Dekkers OM, Lyhne J, et al
2018
Relacorilant
Assessment of Safety,Tolerability,Pharmacokinetics, and Pharmacological Effect of Orally Administered CORT125134: An Adaptive, Double-Blind, Randomized, Placebo-Controlled Phase 1 Clinical Study
Hunt H, Donaldson K, Strem M, et al.
2017
Mifepristone
Evaluation of evidence of adrenal insufficiency in trials of normocortisolemic patients treated with mifepristone
Yuen KCJ, Moraitis A, Nguyen D
2016
Mifepristone
Mifepristone improves octreotide efficacy in resistant ectopic Cushing’s syndrome
Moraitis AG, Auchus RJ
2016
Prevalence of hypercortisolism in type 2 diabetes patients: a systematic review and meta-analysis
Steffensen C, Pereira AM, Dekkers OM, Jørgensen JOL
2016
Prevalence of subclinical hypercortisolism in type 2 diabetic patients from the Rio de Janeiro Type 2 Diabetes Cohort Study
Costa DS, Conceição FL, Leite NC, Ferreira MT, Salles GF, Cardoso CRL
2015
Mifepristone
Association between mifepristone dose, efficacy, and tolerability in patients with Cushing syndrome
Yuen KCJ, Williams G, Kushner H, Nguyen D
2015
Mifepristone
Mifepristone and Cushing syndrome: A commentary
Kennedy L
2015
Mifepristone
Persistent Weight Loss in Patients Treated With Mifepristone for Cushing's Syndrome: Results From the SEISMIC & Long-Term Extension Studies
Fein HG, Vaughan III B, Gross C, et al.
2014
Long-Term Follow-Up in Adrenal Incidentalomas: An Italian Multicenter Study
Morelli V, Reimondo G, Giordano R, et al.
2014
Cardiovascular events and mortality in patients with adrenal incidentalomas that are either non-secreting or associated with intermediate phenotype or subclinical Cushing’s syndrome: a 15-year retrospective study
Di Dalmazi G, Vicennati V, Garelli S, et al.
2014
Cortisol as a Marker for Increased Mortality in Patients with Incidental Adrenocortical Adenomas
Debono M, Bradburn M, Bull M, Harrison B, Ross RJ, Newell-Price J
2014
Mifepristone
Global clinical response in Cushing’s syndrome patients treated with mifepristone
Katznelson L, Loriaux DL, Feldman D, et al.
2013
Mifepristone
A new therapeutic approach in the medical treatment of Cushing’s syndrome: glucocorticoid receptor blockade with mifepristone
Fleseriu M, Molitch ME, Gross C, Schteingart DE, Vaughan TB, Biller BMK
2013
Mifepristone
Improvement in insulin sensitivity during mifepristone treatment of Cushing syndrome: early and late effects.
Wallia A, Colleran K, Purnell JQ, et al.
2012
Mifepristone
Mifepristone, a glucocorticoid receptor antagonist, produces clinical and metabolic benefits in patients with Cushing’s syndrome
Fleseriu M, Biller BMK, Findling JW, et al.
2001
Mifepristone
Successful long-term treatment of refractory Cushing's disease with high-dose mifepristone (RU 486)
Chu JW, Matthias DF, Belanoff J, Schatzberg A, Hoffman AR, Feldman D